Clinical Trial Update: Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated imatinib mesylate as maintenance therapy after donor stem cell transplantation in Philadelphia chromosome-positive leukemia. The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED